Ratings Generali Xetra

Equities

ASG

IT0000062072

Real-time Estimate Tradegate 11:42:07 2024-06-05 am EDT 5-day change 1st Jan Change
23.86 EUR +0.95% Intraday chart for Generali +2.10% +24.39%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • With regards to fundamentals, the enterprise value to sales ratio is at 0.86 for the current period. Therefore, the company is undervalued.
  • The company has a low valuation given the cash flows generated by its activity.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.

Ratings chart - Surperformance

Sector: Life & Health Insurance

1st Jan change Capi. Investor Rating ESG Refinitiv
+24.39% 39.91B -
+12.28% 78.47B
B-
+7.05% 50.03B
B
+5.70% 50B
B+
+20.29% 46.35B
B+
+12.79% 42.36B
B+
-1.27% 28.8B
B
-7.77% 28.33B
B-
-15.17% 26.27B
A-
+23.50% 25.57B
A
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes